Metastatic Castration-resistant Prostate Cancer Clinical Trial
— PROWESsOfficial title:
a French Observational Prospective Multicenter Study of Adult Patients Treated in the Real-life Setting With Olaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer
This French non-interventional prospective multicenter cohort study is conducted to study the added value of olaparib in the treatment of patients with mCRPC in the real world setting in terms of treatment sequencing, effectiveness, safety and BRCA testing patterns and thus inform future clinical practice.
| Status | Recruiting |
| Enrollment | 300 |
| Est. completion date | October 13, 2028 |
| Est. primary completion date | October 13, 2028 |
| Accepts healthy volunteers | No |
| Gender | Male |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Adult male patients (= 18 years old) - With metastatic castration-resistant prostate cancer - Who have initiated olaparib within the last two months of study entry, or for whom the decision to be treated with olaparib has been made by their physician - Who have been informed and are not opposed to this data collection Exclusion Criteria: - Patients opposed to the collection of their data - Patients participating in a clinical trial with an investigational prostate cancer targeted drug within 30 days prior to Olaparib initiation |
| Country | Name | City | State |
|---|---|---|---|
| France | Research Site | Amiens | |
| France | Research Site | Angers Cedex 9 | |
| France | Research Site | Antony | |
| France | Research Site | Argenteuil | |
| France | Research Site | Avignon | |
| France | Research Site | Besancon | |
| France | Research Site | Bordeaux | |
| France | Research Site | Challes Les Eaux | |
| France | Research Site | Chambray Les Tours | |
| France | Research Site | Chambray Les Tours | |
| France | Research Site | Champigny Sur Marne | |
| France | Research Site | Clermont-ferrand Cedex 1 | |
| France | Research Site | Compiegne Cedex | |
| France | Research Site | Epagny METZ Tessy | |
| France | Research Site | Epagny METZ Tessy | |
| France | Research Site | FORT DE France | |
| France | Research Site | Frejus Cedex | |
| France | Research Site | Frejus Cedex | |
| France | Research Site | Le Chesnay | |
| France | Research Site | Le Coudray | |
| France | Research Site | Le Coudray | |
| France | Research Site | Le Mans | |
| France | Research Site | Levallois Perret | |
| France | Research Site | Lyon | |
| France | Research Site | Lyon Cedex 09 | |
| France | Research Site | Mantes La Jolie | |
| France | Research Site | Marseille | |
| France | Research Site | Morlaix | |
| France | Research Site | Nancy | |
| France | Research Site | Nancy | |
| France | Research Site | Nantes | |
| France | Research Site | Nice Cedex 2 | |
| France | Research Site | Nice Cedex 2 | |
| France | Research Site | Orléans | |
| France | Research Site | Orléans | |
| France | Research Site | Paris | |
| France | Research Site | Pointe A Pitre | |
| France | Research Site | Pontoise | |
| France | Research Site | Quint Fonsegrives | |
| France | Research Site | Rouen | |
| France | Research Site | Saint Denis- LA Reunion | |
| France | Research Site | Saint Doulchard | |
| France | Research Site | Saint Mande | |
| France | Research Site | Saint-etienne | |
| France | Research Site | Saint-etienne | |
| France | Research Site | Saint-etienne Cedex 1 | |
| France | Research Site | Saint-gregoire | |
| France | Research Site | St Nazaire | |
| France | Research Site | Tours | |
| France | Research Site | Tours | |
| France | Research Site | Vannes | |
| France | Research Site | Vantoux |
| Lead Sponsor | Collaborator |
|---|---|
| AstraZeneca |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Time to treatment discontinuation (TTD) | TTD is defined as the time from the first day of olaparib treatment to the day that olaparib stopped for whatever reason or the date of death due to any cause, whichever comes first | Up to 36 months from olaparib initiation |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04986423 -
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Terminated |
NCT05489991 -
A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05521412 -
EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T
|
Phase 1/Phase 2 | |
| Terminated |
NCT04556617 -
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
|
Phase 1/Phase 2 | |
| Completed |
NCT02125357 -
Sequencing Abiraterone and Enzalutamide in mCRPC
|
Phase 2 | |
| Recruiting |
NCT06052306 -
A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Men With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
|
Phase 1 | |
| Recruiting |
NCT05917470 -
A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05519449 -
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
|
Phase 1 | |
| Terminated |
NCT05301062 -
A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels
|
||
| Recruiting |
NCT05383079 -
Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04060394 -
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
|
Phase 1/Phase 2 | |
| Completed |
NCT01942837 -
Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT05458544 -
[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04879589 -
Phase 1 Study of ATRS-2002 in Healthy Male Adults
|
Phase 1 | |
| Recruiting |
NCT03230734 -
Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT05116579 -
Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)
|
||
| Active, not recruiting |
NCT03732820 -
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT05005728 -
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT05762536 -
Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC
|
Phase 2 |